Intralesional triamcinolone plus gentamicin versus triamcinolone alone for keloid: a two-center cohort study.
Park Joseph Kyu-Hyung JK, Choi Nakwon N, Kim Jong-Ho JH, Kim Baek-Kyu BK et al.
Keloid recurrence remains common after intralesional triamcinolone acetonide (TAC), the first-line therapy, and microbial colonization of the deep dermis has been implicated in keloid pathobiology; however, TAC combined with an antimicrobial has not been tested in a controlled comparison. We conducted a two-center retrospective cohort study comparing intralesional TAC plus gentamicin with TAC alone in adults with keloid. The primary outcome was change in the Vancouver Scar Scale (VSS) from baseline to a standardized 12-month post-treatment assessment, scored independently by two blinded plastic surgeons (ICC 0.90) and analyzed by baseline-adjusted analysis of covariance; a paired survey cohort (n = 109) provided recurrence and symptom outcomes. Among 48 patients (24 per group), VSS reduction was threefold greater with TAC plus gentamicin than with TAC alone (-3.00 vs -1.04; adjusted β = -2.00; 95% confidence interval [CI], -2.86 to -1.14; p < 0.001; Cohen d = 1.27), and 29% versus 0% achieved at least 50% reduction. The effect persisted after adjusting for session number and follow-up (E-value, 5.8). The survey cohort reported a higher recurrence-free proportion, longer time to recurrence, and faster symptom relief. Adding gentamicin to intralesional TAC was associated with greater scar improvement, but treatment was confounded with site of care; randomized confirmation is required before clinical adoption.